Phase 0 - Microdosing strategy in clinical trials.

Indian J Pharmacol

Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Hyderabad, India.

Published: November 2008

Drug development is an activity that is long, complex and expensive. In 2004, attrition in the drug development paradigm prompted the US Food and Drug Administration (FDA) to introduce its 'Critical Path' document, which highlighted the serious discordance between major scientific advances and limited drug development process. One issue addressed was that of microdosing. The concept of microdosing involves the use of extremely low, nonpharmacologically active doses of a drug to define the pharmacokinetic profile of the medication in human subjects. Microdosing, thus, appears as a new viable concept in the 'toolbox' of the drug development activity. It appears that microdosing strategy could complement standard animal-to-human scaling, redefining the existing concept of phase I clinical research. In future, when research methods and technology involved in Phase 0 studies become more sophisticated, human microdosing may be applied to a number of drugs developed subsequently.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025138PMC
http://dx.doi.org/10.4103/0253-7613.45147DOI Listing

Publication Analysis

Top Keywords

drug development
16
microdosing strategy
8
development activity
8
drug
6
microdosing
5
phase microdosing
4
strategy clinical
4
clinical trials
4
trials drug
4
development
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!